CAMI develops next-generation immunotherapies and molecular treatments for cancer, autoimmune disorders and infectious diseases by accelerating discovery, commercialization and biomedical workforce training.
No Applicants // Limit: 1 // Tickets Available: 1
Limiting Language
An applicant may submit only one application in response to the NOFO. An entity may be proposed as a subrecipient in more than one application. Applications under which two or more entities (project partners) would carry out the federal award will be considered. However, only one entity may be the applicant for the NOFO; any others must be proposed as subrecipients. See the Application Resource Guide for additional information on subawards.
No Applicants // Limit: 1 // Tickets Available: 1
Limiting Language
Only one proposal will be considered by ECA from each applicant organization. In cases where more than one submission from an applicant appears in grants.gov, ECA will only consider the submission made closest in time to the NOFO deadline; that submission would constitute the one and only proposal ECA would review from that applicant.
Executive Summary
Priority Region: EUR
No Applicants // Limit: 1 // Tickets Available: 1
Limiting Language
Only one proposal will be considered by ECA from each applicant organization. In cases where more than one submission from an applicant appears in grants.gov, ECA will only consider the submission made closest in time to the NOFO deadline; that submission would constitute the one and only proposal ECA would review from that applicant.
Executive Summary
No Applicants // Limit: 1 // Tickets Available: 1
Limiting Language
Only one application per eligible applicant may be submitted as determined by the applicant Universal Entity Identifier (UEI) number.
Executive Summary
The National Earthquake Hazards Reduction Program (NEHRP) is a coordinating program for earthquake monitoring, research, implementation, education, and outreach activities developed and conducted by these four agencies:
• Federal Emergency Management Agency;
The IRB evaluates every research protocol according to the ethical principles described in the Belmont Report and according to the specific regulatory criteria outlined in the Common Rule (45 CFR 46) and, when applicable, FDA regulations (21 CFR 50 and 56).
The “Continuing Review Not Required” notification is generated by eIRB when a Minimum Risk, Exempt, or Expedited study that previously had an expiration date in the old IRB system is migrated, and no longer has an IRB approval end date in the new eIRB system. The notification is automated, and you might receive it multiple times; however, no action is required from the Principal Investigator or the study team.
The “Response Time Exceeded’ notification is an auto-generated weekly reminder when a Clarification Request response is pending in eIRB. The notification serves to alert the Principal Investigator and study team that a reply is needed. It does not mean that the response time has expired. The notifications will continue every 7 days until a response is submitted to the IRB.
All investigators and research personnel must complete a Research Certification for each study they are involved with before IRB approval is granted. Note: these study-specific Research Certifications are in addition to the annual conflict of interest (COI) Disclosure Certification.
Research Certifications are integrated with eIRB in two ways:
Limit: 4 // Tickets Available: 3
A.J. Scott (COM-T)
The University of Arizona Cancer Center (UACC) is coordinating this limited submission. For more information please contact: UACC-PreAward.
Limiting Language